SCHEMBL2529176

SCHEMBL2529176

COC(=O)C(C)CN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
HTT P42858 2/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EPHX1 P07099 1/20 0.43
ABCB1 P08183 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
GPR119 Q8TDV5 4/20 0.42
HPGD P15428 1/20 0.41
CYP2D6 P10635 1/20 0.41
NR1H2 P55055 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2529177 1.00 ALDH1A1 (0.48) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL3720593 0.87 ALDH1A1 (0.44) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL27557042 0.87 ALDH1A1 (0.44) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL24027253 0.85 ABCB1 (0.45) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL21806003 0.85 ABCB1 (0.45) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL1705499 0.85 ALDH1A1 (0.49) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL5859962 0.84 USP2 (0.43) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL27385307 0.84 USP2 (0.43) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL3158801 0.84 USP2 (0.45) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL18852406 0.83 PIK3CD (0.58) ALDH1A1HTTNPC1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2014-10-23 US disclosed
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity ERBB2, ABL1, FLT1 ALDH1A1 4061/4885HTT 722/4885NPC1 3881/4885
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY FLT1, KDR, FLT4 ALDH1A1 2750/4885HTT 1001/4885NPC1 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.